Pre-earnings options volume in CytomX Therapeutics is 10.4x normal with calls leading puts 7:1. Implied volatility suggests the market is anticipating a move near 56.8%, or $2.29, after results are released. Median move over the past eight quarters is 3.5%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
- CytomX Therapeutics upgraded to Buy from Hold at Jefferies
- Biotech Alert: Searches spiking for these stocks today
- CytomX Therapeutics extends rally, shares up 218% to $5.19
- BMO sees CytomX rallying after ‘surprise’ data announcement